← Leaderboards
Christopher D Porada
Wake Forest University Health Sciences
$6,964,841
Attributed
$12,933,031
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,933,031 · 7
By mechanism
R01$12,163,513 · 6
U01$769,518 · 1
Top collaborators
- Graca Duarte Almeida-Porada20 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- James C. Rose$15,077,307
- Graca Duarte Almeida-Porada$10,981,686
- Jorge Pablo Figueroa$5,892,821
- Michael A Thomas$604,761
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmuneSheepLifeVectorAnimal ModelGene TherapyHemophilia ABirthTransgenesProteinsF8 GeneInheritedDoseIncidencePre-ClinicalTreatment EfficacyGenetic DiseasesProductionPrenatalAdultSafetyCurative TreatmentsEngraftment
Grant awards (25)
Targeted conditioning to maximize prenatal HSC engraftment for SCD$665,070
R01 · FY2025 · HL
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$652,874
R01 · FY2025 · HL
Using human liver tissue equivalents to optimize AAV-mediated GT and better define age-related clinical risks$383,800
R01 · FY2025 · HL
Targeted conditioning to maximize prenatal HSC engraftment for SCD$662,949
R01 · FY2024 · HL
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$648,076
R01 · FY2024 · HL
Using human liver tissue equivalents to optimize AAV-mediated GT and better define age-related clinical risks$383,921
R01 · FY2024 · HL
Targeted conditioning to maximize prenatal HSC engraftment for SCD$716,640
R01 · FY2023 · HL
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$673,905
R01 · FY2023 · HL
Using human liver tissue equivalents to optimize AAV-mediated GT and better define age-related clinical risks$397,789
R01 · FY2023 · HL
Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A$707,639
R01 · FY2022 · HL
Prenatal Cell and Gene Therapy for Hemophilia A$698,903
R01 · FY2020 · HL
cGMP Manufacture Of FVIII-Expressing Placental Cells For Hemophilia A$383,839
U01 · FY2020 · HL
Prenatal Cell and Gene Therapy for Hemophilia A$692,734
R01 · FY2019 · HL
Postnatal Cell-Based Therapies for Hemophilia A$577,601
R01 · FY2019 · HL
cGMP Manufacture Of FVIII-Expressing Placental Cells For Hemophilia A$385,679
U01 · FY2019 · HL
Prenatal Cell and Gene Therapy for Hemophilia A$675,825
R01 · FY2018 · HL
Postnatal Cell-Based Therapies for Hemophilia A$577,601
R01 · FY2018 · HL
Prenatal Cell and Gene Therapy for Hemophilia A$746,740
R01 · FY2017 · HL
Postnatal Cell-Based Therapies for Hemophilia A$606,184
R01 · FY2017 · HL
Postnatal Cell-Based Therapies for Hemophilia A$698,612
R01 · FY2016 · HL
In Utero Gene Therapy$191,150
R01 · FY2006 · HD · contact PI
In Utero Gene Therapy$195,750
R01 · FY2005 · HD
In Utero Gene Therapy$195,750
R01 · FY2004 · HD
In Utero Gene Therapy$195,750
R01 · FY2003 · HD
In Utero Gene Therapy$218,250
R01 · FY2002 · HD